(b)(4).During processing of this complaint, attempts were made to obtain complete event, patient and device information.The device was not returned for evaluation.Based on the information reviewed, a conclusive cause for the reported difficulty to deploy could not be determined.A review of the lot history record revealed no manufacturing nonconformities that would have contributed to this complaint.Additionally, a review of the complaint history identified no other incidents from this lot.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that the patient presented with severe chest pain.The procedure on (b)(6) 2017 was to treat a lesion located in the proximal to mid left anterior descending (lad) artery with a chronic total occlusion.Vessel sizing was performed with intra-vascular ultrasound which determined that the vessel size was 3.5mm.Pre-dilatation of the mid lad was performed with a 3.0x12mm nc trek with residual stenosis reduced to less than 10%.A 3.0x18mm absorb gt1 was implanted smoothly.A second absorb gt1 (3.5x18mm) was advanced for overlap with the first 3.0x18mm absorb gt1; however, during expansion of the 3.5x18mm absorb gt1, the scaffold suddenly retreated from the original location.The scaffold was deployed partially in the target lesion; however, the scaffold edge was found to be protruding 3mm into the left circumflex.Timi blood flow was 3 and the patient was without any discomfort.The patient was discharged on dual anti-platelet therapy (dapt) on (b)(6) 2017.On the third day after discharge, (b)(6) 2017, the patient went back to the hospital with a severe headache.A brain computer tomography was performed and an intracranial hemorrhage was identified.The consulting neurological surgeon stated the intracranial hemorrhage was caused by taking ticagrelor.The patient's dapt was stopped to avoid expanding the intracranial hemorrhage range.The patient's vital signs are stable and the intracranial hemorrhage is controlled but not resolved.The patient is hospitalized in the intensive care unit for observation.If the patient's condition is stable, the patient is expected to be discharged on (b)(6) 2017.No additional information was provided.
|